Progressive Care Inc (RXMD)

[Jimmy Quick]

Here's my take to help make sense.

1. RXMD doesn't do glasses prescriptions, they do medication prescriptions. Over 318,000 of them annually, and that is increasing by 35% each year.

2. RXMD quarterly, and annually audited Financial Statements are available for anyone's viewing pleasure on OTCMarkets.com under the Disclosure tab. Thats soon to be 3 years of audited financial statements followed by SEC registration.

3. RXMD PRs their accomplishments regularly and are very transparent. Newest was 17% revenue and 37% prescription increase, the one prior was 2 new pharmacy locations in ORLANDO and Davie, FL which are already producing $18 million in annual NET revenues.

4. Institutional Investors will be buying RXMD shares.

5. Chicago Ventures does not currently hold any shares of RXMD, and Chicago Ventures will not be able to convert the funds (used for acquisitions) to shares for close to a year from now which could see RXMD over a $1 since the shares have absoluetly no maximum price, if ProgressiveCare doesn't end up paying off a portion in cash, which they have done in the past. Also, Chicago Ventures, per agreement is not allowed to trade any shares of RXMD in any fashion after close of the deals and only are allowed to trade converted shares, and Chicago Ventures is subject to a 10% volume leak-out clause.

Terms are Tremendously Improved

I had already went through and compared terms.

Reduced rates, better conversion factor by 10%, no maximum share price for conversion, no shorting. These terms are phenomenal compared to 2016 agreement.

Increase in 3rd agreement is due to already having an existing debt agreement and a larger debt amount, makes sense. All other terms were identical, and great compared to 2016. We could be converting this debt @ $1 per share a year from now.. That would be like 4.4 million shares.